BNP Paribas Financial Markets trimmed its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 39.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,156 shares of the biotechnology company’s stock after selling 27,941 shares during the period. BNP Paribas Financial Markets’ holdings in United Therapeutics were worth $20,541,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the stock. Darwin Global Management Ltd. acquired a new stake in United Therapeutics during the third quarter worth approximately $317,617,000. Norges Bank acquired a new position in shares of United Therapeutics during the 4th quarter valued at $293,418,000. Baillie Gifford & Co. purchased a new stake in United Therapeutics during the 4th quarter worth $157,390,000. UBS Group AG boosted its stake in shares of United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after buying an additional 70,445 shares during the last quarter. Finally, Soleus Capital Management L.P. grew its holdings in United Therapeutics by 35.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 209,794 shares of the biotechnology company’s stock worth $60,284,000 after acquiring an additional 54,400 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.
United Therapeutics Trading Up 0.4%
UTHR stock opened at $549.87 on Friday. The business’s 50 day simple moving average is $568.23 and its 200 day simple moving average is $518.83. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The firm has a market capitalization of $23.34 billion, a PE ratio of 20.30, a PEG ratio of 1.78 and a beta of 0.57.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on UTHR. Bank of America raised their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. HC Wainwright raised their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Finally, Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $619.42.
Get Our Latest Stock Report on UTHR
Insiders Place Their Bets
In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,311,581.28. This trade represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at $22,185,323.93. This represents a 19.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 624,043 shares of company stock worth $351,649,680. Company insiders own 8.60% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
- Five stocks we like better than United Therapeutics
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
